MedTrace Logo

Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

NCT00673335 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2024-07-01

No results posted yet for this study

Summary

RATIONALE: Letrozole may prevent breast cancer in postmenopausal women with a BRCA1 or BRCA2 mutation.

PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in preventing breast cancer in postmenopausal women with a BRCA1 or BRCA2 mutation.

Conditions

  • brca1 Mutation Carrier
  • brca2 Mutation Carrier
  • Breast Cancer
  • Hereditary Breast/Ovarian Cancer (brca1, brca2)

Interventions

DRUG

letrozole

DRUG

Placebo

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Pascal Pujol, MD · Hopital Arnaud de Villeneuve

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
69 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2019-06-30
Completion
2023-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00673335 on ClinicalTrials.gov